<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-113 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-113</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-113</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <p><strong>Paper ID:</strong> paper-4da53b43c184eb9b9a3103a77957077abbc66474</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/4da53b43c184eb9b9a3103a77957077abbc66474" target="_blank">Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Thoracic Disease</p>
                <p><strong>Paper TL;DR:</strong> Current classification differentiates between preinvasive lesions (atypical adenomatous hyperplasia and in situ ADC), minimally invasive ADC (MIA) and invasive ADC, which allows more targeted treatments through two distinct strategies, genome-guided therapy and immunotherapy.</p>
                <p><strong>Cost:</strong> 0.021</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e113.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e113.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NF1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neurofibromin 1 (NF1) mutation / loss</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Loss-of-function mutations in NF1, a negative regulator of RAS, are reported in lung adenocarcinoma and often occur without other canonical drivers, implicating NF1 as a putative driver in otherwise oncogene-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Review cites TCGA and other lung ADC cohorts; NF1 observations drawn from TCGA-derived analyses and clinical series (reference to Redig et al. 2016). No dedicated driver-negative cohort is defined in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Implicit: tumors lacking canonical actionable drivers (EGFR/KRAS/BRAF/MET/ERBB2 and translocations such as ALK/ROS1/RET); NF1-mutant tumors are noted to frequently have no other somatic alteration.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Not explicitly enumerated for NF1-only tumors; review states ~70–75% of ADC have identifiable drivers overall (implying ~25–30% remain driver-negative); NF1-mutant tumors reportedly have no other somatic alteration in ~70% of NF1 cases (per cited literature).</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Reported from TCGA / NGS-based somatic mutation catalogs (whole-exome/NGS referenced); curation via TCGA and cBioPortal is described in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>NF1 loss-of-function mutations</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>SNV/indel (loss-of-function mutation)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>NF1 → negative regulator of RAS; implicates RAS/MAPK pathway (RTK/RAS/RAF-related pathway via release of RAS suppression).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Review states ~70% of NF1-mutant lung cancers exhibit no other somatic alteration, but does not give absolute counts of NF1 within driver-negative subset.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Table 2 (reviewed sources): NF1 mutations ~8.3% (TCGA) / ~11% (cBioPortal) of lung ADC.</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Occasionally co-occurs with KRAS (~15% of NF1-mutant cases have concurrent KRAS), but most NF1-mutant tumors (~70%) exhibit no other somatic alteration, consistent with NF1 acting as the (sole) driver in many cases.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Statistical recurrence in TCGA-level datasets; biological plausibility because NF1 is a RAS negative regulator; observation of NF1-mutant tumors lacking other drivers (mutual exclusivity-like pattern in many cases) cited as supportive.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No functional experiments reported in this review; the review cites the literature (clinical/molecular characterization) but does not describe in-paper functional assays for NF1.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Review notes NF1 mutation has become a potential therapeutic target (cites literature) but provides no direct therapeutic/clinical response data in this paper; suggests RAS-pathway targeting rationale but no specific validated therapy reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>No specific expression/proteomic signatures for NF1-mutant/driver-negative tumors are detailed in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Review does not give TMB or mutational signature specifically for NF1-mutant or driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Review states NF1-mutant patients share clinical characteristics and prognosis similar to KRAS-mutant cases; specific demographics not detailed here.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Authors note that co-occurrence in a minority (~15%) with KRAS complicates interpretation; review emphasizes limitations of existing datasets and the need for further validation (functional studies, therapeutic studies).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Loss of NF1 relieves negative regulation of RAS → increased RAS/MAPK signaling driving tumorigenesis in tumors that otherwise lack canonical RTK/RAS/RAF oncogenic alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e113.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e113.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MET ex14 / MET amplification</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET exon 14 skipping alterations and MET gene amplification</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Alterations that affect MET exon 14 (causing exon skipping) or focal MET amplification activate MET signaling; these events are described as targetable drivers in some lung ADCs that may otherwise be considered driver-negative.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Review summarizes frequency from TCGA/cBioPortal and clinical sequencing studies; no single driver-negative cohort is defined in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Implicit: tumors negative for common drivers (EGFR/KRAS/BRAF/ALK/ROS1 etc.); MET ex14 is discussed as an additional actionable alteration to screen for in such cases.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Not explicitly given for MET ex14 among driver-negative tumors; review implies adding MET ex14 screening reduces the driver-negative fraction.</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Reported detection via NGS and copy-number assays; review recommends extending screening and refers to targeted NGS and clinical sequencing; also mentions MET amplifications identified by copy-number analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>MET exon 14 alterations (splicing/exon-skipping) and MET gene amplification</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>Splice alteration (exon skipping) and copy-number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>MET receptor tyrosine kinase → HGF/MET signaling; activates downstream PI3K/AKT, RAS/MAPK pathways (RTK pathway).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Not directly provided; Table 2 lists MET ex14 ~4.3% (TCGA) / ~8% (cBioPortal) overall, suggesting a proportion of previously driver-negative tumors will harbor MET ex14.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>MET ex14: 4.3% (TCGA) and 8% (cBioPortal) per Table 2; MET amplification listed separately as 2.2% (TCGA) / 4% (cBioPortal).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Review states MET mutations are mutually exclusive with KRAS and EGFR alterations; MET amplification associated with resistance to EGFR-guided therapy when present as acquired event.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Recurrence in genomic datasets; biological plausibility as activating MET; clinical response evidence cited (case series/clinical reports) where MET ex14–positive tumors responded to MET inhibitors (crizotinib) per recent reports referenced in review.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No in-paper functional assays; review cites emerging clinical evidence of response to MET inhibitors (crizotinib) as therapeutic validation.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Review cites 'promising evidence' for crizotinib in MET exon 14–altered or MET-amplified tumors and highlights MET as an actionable target with ongoing clinical investigation (references provided).</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>Not specified in detail for MET ex14–positive tumors in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not specified for MET-ex14 tumors within this review.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Review does not give precise histologic correlations for MET ex14 in driver-negative context; notes MET amplifications can be linked to poorer prognosis and EGFR-TKI resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Review notes earlier ambiguity where some MET mutations were not linked to oncogenic potential; emphasizes need for specific detection of exon 14–altering events and that broad panels/WGS/RNA-seq may be required to catch splice alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>MET exon 14 skipping impairs receptor degradation leading to increased MET stability/signaling, driving oncogenic RTK signaling; focal MET amplification increases receptor abundance and signaling output.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e113.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e113.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS1 fusions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 gene rearrangements/fusions (e.g., CD74-ROS1, EZR-ROS1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent ROS1 fusions produce constitutively active ROS1 kinase fusion proteins and are actionable drivers in a subset of lung adenocarcinomas, often identified in patients who might otherwise be negative for more common drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Review synthesizes literature reporting ROS1 rearrangements in NSCLC/ADC cohorts, often found in young, never-smoker patients; recommended as part of extended screening to reduce driver-negative cases.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Implicit: tumors without common drivers; ROS1 fusions are among additional alterations the review recommends testing to identify drivers in previously negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Not directly provided; ROS1 translocations reported at ~1.7% (TCGA) / ~2% (cBioPortal) overall in Table 2.</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Fusions detected by methods including FISH, targeted RNA sequencing, or other molecular assays; review mentions FISH, PCR, and NGS as methods used in clinical practice.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>ROS1 gene fusions (e.g., CD74-ROS1, EZR-ROS1, SLC24A2-ROS1, FIG-ROS1)</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>Gene fusion / structural rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>ROS1 tyrosine kinase → RTK signaling; downstream activation of MAPK and PI3K pathways (RTK/MAPK-related).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Not stated specifically; frequency overall suggests ROS1 accounts for a small fraction (≈1–2%) of ADC and can explain some driver-negative cases.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>ROS1 fusions: ~1.7% (TCGA) / ~2% (cBioPortal) according to Table 2.</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>ROS1 rearrangements are described as specific for ADC and typically mutually exclusive with other canonical drivers (implied in review).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Recurrent oncogenic fusion architecture; clinical responses to ROS1 inhibitors (crizotinib) provide strong clinical evidence for driver status.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>Functional validation is not performed in this review, but clinical trial/series evidence of sensitivity to crizotinib is cited (Shaw et al.), serving as in-human functional/therapeutic validation.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Crizotinib is cited as effective in ROS1-rearranged NSCLC (clinical responses reported and FDA approval noted in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>Not described specifically for ROS1-positive tumors beyond clinical phenotype (young, never-smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not discussed specifically for ROS1-positive or driver-negative ROS1 cases in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>ROS1 rearrangements frequently observed in Asian young women and never-smokers; specific histologic patterns not detailed in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Authors emphasize need to include ROS1 testing in expanded panels because otherwise these rearrangements could be missed in initial limited testing, contributing to 'driver-negative' classifications.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Chromosomal rearrangement creates ROS1 fusion kinase with constitutive kinase activity → constitutive RTK signaling driving proliferation and survival.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e113.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e113.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF V600E</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF V600E activating mutation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>BRAF V600E is a recurrent activating MAPK-pathway mutation found in a minority of lung adenocarcinomas and is targetable with BRAF and MEK inhibitors, providing a source of actionable driver alterations among tumors without other common drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Reported frequencies derived from TCGA and clinical series; review highlights BRAF as almost exclusive to ADC though low frequency compared with melanoma/colorectal.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Implicit: BRAF testing is part of expanded screening for tumors negative for EGFR/KRAS/ALK/etc.; BRAF-mutant tumors would not be 'driver-negative'.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Not provided specifically for BRAF within driver-negative subset; overall BRAF mutations are 7–10% (review cites both ranges).</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Detected by targeted sequencing / NGS panels; review references clinical trial testing and genomic catalogs.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>BRAF V600E (Val600Glu) substitutions</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>SNV (hotspot activating mutation)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>BRAF → RAS/MAPK pathway (MAPK activation independent of upstream RTKs).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Not specified; overall frequency suggests BRAF explains a small subset of previously driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>BRAF mutations ~7% (TCGA) / ~10% (cBioPortal) per Table 2 and text.</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>BRAF mutations are typically mutually exclusive with EGFR and KRAS in the standard oncogene-mutual-exclusivity paradigm (implied in review).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Hotspot recurrence (V600E), biological mechanism known from other cancers, and clinical trial responses to combined BRAF+MEK inhibition (dabrafenib + trametinib) cited as supporting evidence.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>Clinical activity reported in a phase 2 trial of dabrafenib + trametinib in BRAF V600E–mutant NSCLC (review cites Planchard et al.), serving as therapeutic/functional validation in patients.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Dabrafenib plus trametinib cited with reported activity in metastatic BRAF V600E–positive NSCLC; review notes breakthrough therapy designations for such regimens.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>Not specifically described for BRAF-mutant tumors in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not specified for BRAF-mutant or driver-negative tumors in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Review notes BRAF mutations more likely in smokers and women; not linked to clear prognosis change vs wild-type in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Low overall frequency limits impact on total driver-negative fraction; review suggests including BRAF in extended testing to reduce 'unknown-driver' cases.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>V600E substitution constitutively activates BRAF kinase → downstream MAPK/ERK signaling driving proliferation independent of upstream RTKs.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e113.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e113.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RIT1 / MAP2K1 / NRAS/HRAS / ERBB2 (noncanonical drivers)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Low-frequency noncanonical driver mutations (RIT1, MAP2K1, NRAS, HRAS, ERBB2 alterations)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review lists several lower-frequency recurrent alterations (RIT1, MAP2K1, NRAS/HRAS, ERBB2) identified in lung ADC datasets that can account for subsets of tumors lacking the common drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Frequencies summarized from TCGA and cBioPortal aggregate datasets; no dedicated driver-negative cohort described.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Implicit: these lower-frequency events are additional actionable/driver events to screen for in tumors negative for canonical RTK/RAS/RAF drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Not specified per-event within driver-negative subset; aggregate presence of these low-frequency events contributes to decreasing the driver-negative fraction.</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Detected in WES/targeted NGS analyses reported by TCGA and clinical sequencing aggregated in cBioPortal; review references these platforms in general.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Recurrent mutations in RIT1, MAP2K1 (MEK1), NRAS/HRAS, and ERBB2 alterations (mutations or amplifications)</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>SNV/indel (hotspot or activating mutations) and copy-number amplification (ERBB2 amplification)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>These implicate RAS/MAPK pathway (RIT1, MAP2K1, NRAS/HRAS) and RTK/ERBB signaling (ERBB2/HER2); thus often involve MAPK or RTK pathways (RTK/RAS/RAF-related or adjacent).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Not provided specifically; individual overall frequencies are low (see 'frequency_in_overall_luad').</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Table 2 lists RIT1 ~2.2% (TCGA)/~2% (cBioPortal); MAP2K1 ~0.9% (TCGA)/<1% (cBioPortal); NRAS/HRAS ~0.8% (TCGA)/<1% (cBioPortal); ERBB2 mutations ~1.7% (TCGA)/~1% (cBioPortal); ERBB2 amplifications ~0.9% (TCGA)/~3% (cBioPortal).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Not detailed per-gene in this review; implied that some are mutually exclusive with canonical drivers consistent with oncogene paradigms but specifics are not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Recurrence in TCGA/cBioPortal datasets and known oncogenic mechanisms for some genes (MAP2K1, NRAS/HRAS, ERBB2) provide supportive evidence; review does not present functional proof within this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No new functional validation within this review; some of these genes have known oncogenic roles from other literature, and ERBB2-targeting is established in other cancers (review suggests ERBB2 as a potential target).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Review recommends extended testing for ERBB2 and other lower-frequency drivers; specific therapeutic responses for these rare events are not detailed extensively in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>Not reported specifically for these low-frequency events in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not specified for these subsets in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Not detailed in this review for each low-frequency event.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Low prevalence and limited data in aggregated cohorts make interpretation challenging; review emphasizes need for broader genomic profiling to detect such events.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Activating mutations in MAPK-pathway components or ERBB2-driven RTK signaling lead to MAPK/PI3K pathway activation analogous to canonical drivers, providing alternative oncogenic routes in tumors negative for EGFR/KRAS/ALK/ROS1.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e113.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e113.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Epigenetic DMRs</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Differentially methylated regions (epigenetic alterations) in lung ADC</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review cites a study identifying 15 differentially methylated regions (DMRs) present in lung adenocarcinoma but absent in adjacent normal tissue, proposed as biomarkers and potential targets, suggesting epigenetic mechanisms may contribute to oncogenesis in tumors lacking coding drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>DMR discovery referenced from Daugaard et al.; review does not provide cohort details here but indicates comparisons between tumor and adjacent normal lung tissue.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Review suggests that epigenetic changes can act alongside or in the absence of coding driver mutations and may explain oncogenesis in some tumors without canonical somatic drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Not quantified in relation to DMR-positive/driver-negative tumors in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>DNA methylation microarrays used in the cited study (Daugaard et al.) to identify DMRs.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Recurrent tumor-specific differentially methylated regions (epigenetic silencing/activation)</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>Epigenetic alteration (DNA methylation changes)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>Not specified in detail in this review; DMRs could affect tumor suppressors or regulatory elements influencing pathways relevant to tumorigenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Not provided; Daugaard et al. identified and validated 15 DMRs as ADC-associated vs adjacent normal lung.</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Not discussed.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Presence of tumor-specific recurrent methylation changes absent in adjacent normal tissue and validation across samples cited as supportive; mechanistic driver status remains to be established.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>Review does not report functional validation; it notes potential for these DMRs to serve as biomarkers and eventual therapeutic targets.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Suggested as potential targets for novel treatments in future research; no clinical interventions reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>The DMRs are described as tumor-specific methylation signatures distinguishing ADC from adjacent normal tissue, but not tied explicitly to driver-negative classification in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not specified with respect to DMR-positive tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Not detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Authors note that epigenetic modifications are common but their causal role versus passenger/biomarker role requires further study; functional causality not yet established.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Aberrant DNA methylation at specific regions leads to altered expression of genes (e.g., tumor suppressors), which may enable oncogenic transformation in the absence of canonical coding drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Comprehensive molecular profiling of lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer <em>(Rating: 2)</em></li>
                <li>Targeting MET in Lung Cancer: Will Expectations Finally Be MET? <em>(Rating: 2)</em></li>
                <li>Crizotinib in ROS1 -Rearranged Non-Small-Cell Lung Cancer <em>(Rating: 2)</em></li>
                <li>Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial <em>(Rating: 2)</em></li>
                <li>Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>